Could stem cells slow Huntington's? new trial tests cellavita HD
NCT ID NCT03252535
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This phase 2 trial tested a stem cell therapy called Cellavita HD in 49 people with Huntington's disease. Participants received either a low dose, high dose, or placebo through IV infusions over several months. The study measured changes in motor skills to see if the treatment could slow the disease's progression.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cellavita HD (mesenchymal stem cells)
- What this could lead to
- If successful, this could point toward a treatment that slows or improves motor decline in Huntington's disease.
- What could go wrong
- This is a small, early-phase trial with only 49 participants. Results may not be conclusive, and stem cell therapies carry risks like immune reactions or unknown long-term effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Azidus Brasil Pesquisa Científica e Desenvolvimento Ltda.
Valinhos, São Paulo, 13271-130, Brazil
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a genetic 'Patch' fix Huntington's disease? lab test aims to find out
- Could a brain disease change behavior years before diagnosis?
- Scientists decode gait signatures to spot brain diseases
- Can a One-Page guide spark better End-of-Life talks for dementia patients?
- Blood test could spot Parkinson's earlier, study hopes
- Can a cooking oil protect the brain in Huntington's?